SEC Company Response from Pluri Inc. (PLUR) (CIK 0001158780) (PLUR) — Jun 28, 2017
Pluri Inc. (PLUR) (CIK 0001158780)
Date: June 28, 2017 · CIK: 0001158780 · Accession: 0001178913-17-001956
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-218916
Letter
Pluristem Therapeutics Inc.
MATAM Advanced Technology Park,
Building No. 5
Haifa L3 31905 Israel
June 28, 2017
Via EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street NE
Washington, D.C. 20549
Attn: Christine Westbrook
Re: Pluristem Therapeutics Inc.
Registration Statement on Form S-3
Filed June 23, 2017
File No. 333-218916
Ladies and Gentlemen:
Pluristem Therapeutics Inc. (the “Company”) hereby requests acceleration of the effectiveness of the above-referenced registration statement pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), so that it may become effective on June 30, 2017, at 2:00 p.m., Eastern Time, or as soon thereafter as is practicable.
The Company understands that the Commission will consider this request for acceleration of the effective date of the above-referenced registration statement as a confirmation of the fact that the Company is aware of its responsibilities under the Securities Act and the Securities Exchange Act of 1934, as amended, as they relate to the proposed public offering of the securities specified in the above-referenced registration statement.
Very truly yours,
PLURISTEM THERAPEUTICS INC.
Show Raw Text
CORRESP 1 filename1.htm Pluristem Therapeutics Inc. MATAM Advanced Technology Park, Building No. 5 Haifa L3 31905 Israel June 28, 2017 Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, D.C. 20549 Attn: Christine Westbrook Re: Pluristem Therapeutics Inc. Registration Statement on Form S-3 Filed June 23, 2017 File No. 333-218916 Ladies and Gentlemen: Pluristem Therapeutics Inc. (the “Company”) hereby requests acceleration of the effectiveness of the above-referenced registration statement pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), so that it may become effective on June 30, 2017, at 2:00 p.m., Eastern Time, or as soon thereafter as is practicable. The Company understands that the Commission will consider this request for acceleration of the effective date of the above-referenced registration statement as a confirmation of the fact that the Company is aware of its responsibilities under the Securities Act and the Securities Exchange Act of 1934, as amended, as they relate to the proposed public offering of the securities specified in the above-referenced registration statement. Very truly yours, PLURISTEM THERAPEUTICS INC. By: /s/ Erez Egozi Erez Egozi Chief Financial Officer cc: Oded Har-Even, Esq. Howard E. Berkenblit, Esq.